Иммунотерапия при метастатическом раке почки: ее роль на современном этапе и перспективы клинического использования
Dmitry Nosov, Е. А. Ворошилова, Maria S. Sayapina et al. · 2013
Cited by 0 works.
Authors
References
- Global cancer statistics
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
- Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma
- Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis
- Mechanisms and functional significance of tumour-induced dendritic-cell defects